Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota-Reference-Cited by-同舟云学术

Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lomeli Barbara K.¹,Galbraith Hal¹,Schettler Jared¹,Saviolakis George A.²,El-Amin Wael²,Osborn Blaire³,Ravel Jacques⁴⁵^ORCID,Hazleton Keith⁶,Lozupone Catherine A.⁷,Evans Ronald J.⁸,Bell Stacie J.⁸,Ochsner Urs A.⁸,Jarvis Thale C.⁸,Baqar Shahida³,Janjic Nebojsa⁸

Affiliation:

1. Quintiles Phase One Services, Overland Park, Kansas, USA

2. DynPort Vaccine Company LLC, Frederick, Maryland, USA

3. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

4. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA

5. Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA

6. Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

7. Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

8. Crestone, Inc., Boulder, Colorado, USA

Abstract

CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile , inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01395-19

Reference48 articles.

1. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

2. CDC. 2015. Nearly half a million Americans suffered from Clostridium difficile infections in a single year. https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html.

3. Survey of Health Care–Associated Infections

4. Burden ofClostridium difficileInfection in the United States

5. Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine;Frontiers in Medicine;2024-01-08

2. Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance;European Journal of Medicinal Chemistry;2023-08

3. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08

4. The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects;Biomedicines;2023-02-01

5. Precision Probiotics in Agroecosystems: Multiple Strategies of Native Soil Microbiotas for Conquering the Competitor Ralstonia solanacearum;mSystems;2022-06-28